This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Pai, L. H. Articles by Pastan, I. Search for Related Content PubMed PubMed Citation Articles by Pai, L. H. Articles by Pastan, I.

Antitumor Activity of a Transforming Growth Factor -Pseudomonas Exotoxin Fusion Protein (TGF--PE40)

Laboratory of Molecular Biology, Division of Cancer Biology, Diagnosis and Centers, National Cancer Institute, NIH, Bethesda, Maryland 20892

TGF--PE40 is a chimeric protein composed of transforming growth factor (TGF-) linked to a modified Pseudomonas toxin from which the cell recognition domain has been deleted (PE40). TGF--PE40 has been shown to have cytotoxic effects on human cancer cell lines that express the epidermal growth factor (EGF) receptor on their surface, and when given i.p., it prolongs the survival of nude mice bearing i.p. tumors. Because several normal tissues, including liver, express EGF receptors on their surfaces, it has not been clear that this agent can be used systemically to treat EGF receptor-bearing tumors. In this study, we have delivered TGF--PE40 for 7 days by continuous infusion through a miniosmotic pump placed in the peritoneal cavity of nude immunodeficient mice. Two different human cancer cell lines that express EGF receptors on their surface were implanted s.c. One was A431, an epidermoid carcinoma; the other was DU-145, a prostate carcinoma. By using this mode of continuous i.p. delivery, we were able to achieve a constant serum level of TGF--PE40 that was nontoxic to the mice and yet delayed the growth of both tumors implanted s.c. and caused partial regression of one. We conclude that it is possible to deliver TGF--PE40 systemically and achieve a therapeutic serum level in mice without major toxicity. Although side effects may be expected, this study establishes that there is a therapeutic window for this agent in the therapy of cancers with high numbers of EGF receptors.

¹ To whom requests for reprints should be addressed, at National Cancer Institute, NIH, 9000 Rockville Pike, Bldg. 37, Rm. 4E16, Bethesda, MD 20892.

Received 11/14/90. Accepted 3/21/91.

This article has been cited by other articles:

				P. Cironi, I. A. Swinburne, and P. A. Silver Enhancement of Cell Type Specificity by Quantitative Modulation of a Chimeric Ligand J. Biol. Chem., March 28, 2008; 283(13): 8469 - 8476. [Abstract] [Full Text] [PDF]

				U. Reusch, M. Sundaram, P. A. Davol, S. D. Olson, J. B. Davis, K. Demel, J. Nissim, R. Rathore, P. Y. Liu, and L. G. Lum Anti-CD3 x Anti-Epidermal Growth Factor Receptor (EGFR) Bispecific Antibody Redirects T-Cell Cytolytic Activity to EGFR-Positive Cancers In vitro and in an Animal Model Clin. Cancer Res., January 1, 2006; 12(1): 183 - 190. [Abstract] [Full Text] [PDF]

				M W J d. Brok, G C de Gast, J H M Schellens, and J H Beijnen Targeted toxins Journal of Oncology Pharmacy Practice, December 1, 1999; 5(4): 149 - 165. [Abstract] [PDF]

				I. Benhar and I. Pastan Identification of Residues That Stabilize the Single-chain Fv of Monoclonal Antibodies B3 J. Biol. Chem., October 6, 1995; 270(40): 23373 - 23380. [Abstract] [Full Text] [PDF]

				Y. Tsutsumi, M. Onda, S. Nagata, B. Lee, R. J. Kreitman, and I. Pastan Site-specific chemical modification with polyethylene glycol of recombinant immunotoxin anti-Tac(Fv)-PE38 (LMB-2) improves antitumor activity and reduces animal toxicity and immunogenicity PNAS, July 18, 2000; 97(15): 8548 - 8553. [Abstract] [Full Text] [PDF]